Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D Supplementation and Acute Respiratory Infection in Older Long-Term Care Residents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 60+ years~* Resides in nursing home~Exclusion Criteria:~* Terminal illness (expected survival \<6 months)~* Anticipated discharge within 12 months~* Unable to take whole or crushed tablets~* Active cancer, except squamous/basal cell carcinoma~* Severe malnutrition (body mass index \<18 kg/m2)~* Current immunosuppressive medications (including corticosteroids)~* Renal failure (estimated glomerular filtration rate \< 15 mL/min/1.73m2)~* Currently taking \>1,000 IU/d vitamin D supplementation~* History (or strong family history) of kidney stones~* History of sarcoidosis or other granulomatous disorders associated with hypercalcemia~* Elevated baseline hypercalcemia (albumin-adjusted serum calcium \>10.5 mg/dL)~* Baseline serum 25OHD level ≥ 100 nmol/L~* Inability to provide informed consent and no available healthcare legally authorized representative~* Inability of participant or legally authorized representative to speak/understand English

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High Dose Vitamin D (Type: EXPERIMENTAL): 100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day.
- Standard Dose Vitamin D (Type: ACTIVE_COMPARATOR): 12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).